Education
About Us
Working with TipRanks
Follow Us
Artivion (AORT)
NYSE:AORT
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.03Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong favorable financial and clinical story: double-digit revenue growth, outsized EBITDA expansion, margin improvement, deleveraging, positive clinical data, and clear 2026 guidance. Key challenges remain from the 2024 cybersecurity incident, a softer-than-expected tissue business, an Italian payback adjustment, elevated near-term CapEx and R&D spend, and early-stage commercial execution for new products (AMDS, NEXUS). Overall, positives (growth, margins, clinical/regulatory progress, regional strength, leverage improvement) materially outweigh the operational and legacy headwinds.Company Guidance
Full-Year Revenue and EBITDA Growth
Total adjusted constant currency revenue grew 13% for FY2025 to $443.6M, while adjusted EBITDA grew 26% year-over-year with an adjusted EBITDA margin of 20.2% (up 190 basis points).
Strong Fourth Quarter Results
Q4 adjusted revenues were $118.3M (excluding Italian payback), up 18.5% YoY. Q4 adjusted EBITDA increased ~29% from $17.6M to $22.7M, and adjusted EBITDA margin improved to 19.2% (up ~110 basis points YoY).
Stent Graft Momentum
Stent graft revenues grew 36% YoY in Q4 on a constant currency basis (28% growth when adjusting for the 2024 cyber incident), cited as a foundational growth driver with plans to expand U.S. and Japan commercialization.
On-X Growth and Market Opportunity
On-X revenues grew 24% YoY in Q4 on a constant currency basis. Management forecasts mid-teens growth for On-X in 2026 and identifies a $100M incremental U.S. market opportunity based on new clinical data.
Clinical and Regulatory Progress
Positive clinical updates: AMDS PERSEVERE two-year data reinforced benefits; NEXUS TRIUMPH one-year IDE results showed 94% survival from lesion-related death, 91% free from stroke, and 97% free from renal reinterventions. Fourth/final AMDS PMA module filed; AMDS PMA targeted mid-2026; NEXUS and other PMA timelines noted.
Regional Revenue Strength
Q4 regional constant currency growth: Asia Pacific +32%, North America +18%, EMEA +17%, Latin America +9% YoY, indicating broad geographic momentum.
Balance Sheet and Leverage Improvement
Year-end cash of ~$64.9M and debt of $215.1M; net leverage ratio improved to 1.8x from 3.8x year-over-year, signaling meaningful deleveraging.
2026 Outlook with Continued Growth and Margin Expansion
Guidance for 2026: constant currency revenue growth of 10%-14% (reported revenue $486M-$504M) and adjusted EBITDA of $105M-$110M (18%-22% growth), with expected ~150 basis points of adjusted EBITDA margin expansion at midpoint and slightly positive free cash flow.
Pipeline and Longer-Term TAM Opportunities
ARTISAN (Arecibo LSA) enrollment underway (8 of 132 patients), expected enrollment complete mid-2027 and potential FDA approval in 2029, representing an incremental ~$80M U.S. market opportunity.
AORT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AORT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $40.65 | $36.60 | -9.96% |
Nov 06, 2025 | $47.50 | $44.87 | -5.54% |
Aug 07, 2025 | $32.70 | $40.95 | +25.23% |
May 05, 2025 | $23.77 | $27.42 | +15.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Artivion (AORT) report earnings?
Artivion (AORT) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Artivion (AORT) earnings time?
Artivion (AORT) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AORT EPS forecast?
AORT EPS forecast for the fiscal quarter 2026 (Q1) is 0.03.